Hypertension Guidelines Flashcards

A 48-year-old commercial truck driver presents for his DOT physical with a blood pressure reading of 164/104 mmHg. He has no history of cardiovascular disease, no target organ damage, and is not currently on antihypertensive medication. Under current FMCSA hypertension guidelines, what is the most appropriate certification decision?

Answer: Issue a one-time, 3-month certificate and require the driver to return with BP controlled below 140/90 mmHg for full certification

A BP of 164/104 mmHg falls into Stage 2 hypertension (160–179/100–109 mmHg) under FMCSA guidelines. For Stage 2, the examiner may issue a one-time, 3-month certificate. The driver must return with BP below 140/90 mmHg to be eligible for the standard 1-year certificate. This one-time 3-month extension cannot be repeated — if BP remains in Stage 2 range at the follow-up, no further certificates may be issued until control is achieved. Stage 1 (140–159/90–99) allows a 1-year cert; Stage 3 (≥180/110) results in disqualification.

A 55-year-old CDL driver is newly started on doxazosin (Cardura) 1 mg daily for hypertension. His BP at today's exam is 132/84 mmHg and he reports no symptoms. Which of the following is the PRIMARY safety concern the NRCME medical examiner must address before issuing a medical certificate?

Answer: First-dose and dose-escalation orthostatic hypotension, which may cause syncope or impaired vehicle control

Alpha-1 adrenergic blockers such as doxazosin are well-known to cause significant first-dose orthostatic hypotension, particularly within 1–3 hours of the initial dose or after dose increases. This abrupt BP drop can cause dizziness, lightheadedness, or syncope — directly hazardous when operating a commercial motor vehicle. FMCSA guidelines require examiners to evaluate whether antihypertensive medications produce side effects incompatible with safe driving. Reflex tachycardia is characteristic of direct vasodilators (hydralazine), not alpha blockers. QT prolongation and hyponatremia are not primary concerns with this drug class.

A 58-year-old long-haul driver has blood pressure of 170/100 mmHg despite being prescribed three antihypertensive agents, including a diuretic at maximal dose. He reports persistent muscle cramps and fatigue. Serum potassium is 3.0 mEq/L and serum sodium is 144 mEq/L. Which underlying etiology should the medical examiner most strongly suspect and flag for specialist referral?

Answer: Primary hyperaldosteronism (Conn's syndrome)

The triad of resistant hypertension (uncontrolled despite ≥3 agents including a diuretic), spontaneous or diuretic-exacerbated hypokalemia, and normal serum sodium is the classic presentation of primary hyperaldosteronism. Excess aldosterone causes renal potassium wasting and sodium retention, driving both the BP elevation and hypokalemia. It is the most common secondary cause of resistant hypertension, present in up to 20% of refractory cases. Pheochromocytoma would present with paroxysmal symptoms (headache, diaphoresis, palpitations). Renovascular disease typically does not cause hypokalemia unless associated with secondary hyperaldosteronism. OSA is common but does not directly cause hypokalemia.

A commercial driver is taking clonidine 0.3 mg twice daily for hypertension. His in-office BP is 126/80 mmHg. He mentions that he sometimes forgets his midday dose when on long hauls. Which of the following represents the most clinically significant concern the NRCME examiner should document regarding this driver's medication regimen?

Answer: Missing doses of clonidine can trigger hypertensive rebound, potentially reaching Stage 3 levels and causing hypertensive emergency

Clonidine is a centrally acting alpha-2 agonist that suppresses sympathetic outflow. Abrupt discontinuation or missed doses — particularly at higher doses — can trigger severe rebound hypertension, sometimes exceeding the original pretreatment BP and reaching Stage 3 (≥180/110 mmHg) or causing hypertensive crisis. This is especially concerning for long-haul drivers who may miss doses while on the road. Additionally, clonidine's sedative CNS effects can impair alertness, but the rebound phenomenon is the most acutely dangerous issue. Clonidine is not explicitly prohibited by FMCSA, but compliance and side-effect risks must be carefully documented by the examiner.

A driver's blood pressure is measured at 172/108 mmHg during his DOT examination. He presents documentation of 21 home blood pressure readings taken over the past 3 weeks, averaging 124/76 mmHg, obtained using a validated, calibrated home monitor. He insists his office BP is due to 'white coat hypertension.' Under FMCSA guidelines, how should the medical examiner proceed?

Answer: Apply the in-office measurement; issue a one-time 3-month certificate at Stage 2, and require a follow-up examination with controlled BP

Under FMCSA medical examination guidelines, the blood pressure value recorded during the physical examination is the operative value — home readings and self-reported measurements cannot replace or override the in-office measurement for certification purposes. A reading of 172/108 mmHg meets Stage 2 criteria (160–179/100–109 mmHg), which qualifies the driver for a one-time, 3-month certificate with the requirement to return with BP below 140/90 mmHg. Ambulatory monitoring is not part of the FMCSA standard certification protocol. Home readings, regardless of their number or validation, do not substitute for the examination-room measurement under current federal guidelines.

A 61-year-old driver was disqualified 5 months ago with a blood pressure of 192/116 mmHg (Stage 3). He returns today on a three-drug antihypertensive regimen with a BP of 136/82 mmHg. An EKG shows left ventricular hypertrophy (LVH) by voltage criteria with no ST changes. He has no chest pain, dyspnea, or functional limitations. What is the most appropriate FMCSA certification decision?

Answer: Issue a 1-year medical certificate, as his blood pressure is now below 140/90 mmHg

Under FMCSA hypertension guidelines, once a previously disqualified Stage 3 driver achieves BP control below 140/90 mmHg on treatment, he is eligible for certification — typically a 1-year certificate reflecting the treatment requirement. There is no provision permanently restricting drivers to 3-month certificates solely because of a prior Stage 3 reading. LVH by voltage criteria on EKG alone, without functional impairment, ST changes, or evidence of heart failure, does not independently disqualify a commercial driver. LVH is a marker of long-standing hypertension but must be evaluated in the context of overall cardiovascular function. The examiner should document it and may request cardiology input if functional status is uncertain, but it is not an automatic bar to certification when the driver is asymptomatic and BP is controlled.